Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalent Inc (NY: CTLT )

58.73 +0.13 (+0.22%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalent Inc

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Highlander Partners Announces the Signing of a Definitive Agreement to Sell Bettera Brands to Catalent
From Highlander Partners
Via Business Wire
A Peek Into The Markets: US Stock Futures Edge Higher After S&P 500, Nasdaq Hit Record Highs
Pre-open movers U.S. stock futures traded slightly higher in early pre-market trade after the S&P and the Nasdaq hit record closing highs in the previous session following... 
Via Benzinga
Topics Stocks
Exposures US Equities
5 Stocks To Watch For August 30, 2021
Some of the stocks that may grab investor focus today are: Wall Street expects Zoom Video Communications Inc (NASDAQ: ZM) to report quarterly earnings at $1.16 per share on... 
Via Benzinga
Earnings Scheduled For August 30, 2021
Companies Reporting Before The Bell Catalent Inc (NYSE: CTLT) is expected to report quarterly earnings at $1.03 per share on revenue of $1.14 billion. Cloudera, Inc. (NYSE: CLDR... 
Via Benzinga
Catalent's Debt Overview
Shares of Catalent (NYSE:CTLT) rose by 23.76% in the past three months. Before having a look at the importance of debt, let us look at how much debt Catalent has. Catalent... 
Via Benzinga
Catalent: Q3 Earnings Insights
Shares of Catalent (NYSE:CTLT) decreased 0.1% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 64.00% over the past... 
Via Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 25) Abbvie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures COVID-19
A Look Into Catalent's Price Over Earnings
In the current market session, Catalent Inc. (NYSE:CTLT) is trading at $126.21, after a 0.1% drop. However, over the past month, the stock went up by 8.33%, and in... 
Via Benzinga
EMA Approves Additional Sites To Boost Output Capacity For mRNA-Based COVID-19 Vaccines
European Medical Agency (EMA) has approved additional manufacturing sites for mRNA-based coronavirus vaccines developed by Pfizer Inc (NYSE: PFE) - ... 
Via Benzinga
Exposures COVID-19
Unusual Options Activity Insight: Catalent
On Monday, shares of Catalent (NYSE:CTLT) saw unusual options activity. After the option alert, the stock price moved up to $121.14. Sentiment: BEARISH Option Type: TRADE Trade... 
Via Benzinga
Catalent, Inc. Announces Fourth Quarter Fiscal Year 2021 Earnings Conference Webcast
From Catalent, Inc.
Via Business Wire
Catalent Achieves 97% Renewable Electricity Sourcing and Commits to Science-Based Target Initiative to Reduce Carbon Footprint
From Catalent, Inc.
Via Business Wire
2 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go... 
Via Benzinga
Catalent Plans $100M Expansion Of Biologics Capabilities At Italian Vaccine Plant
Catalent Inc (NYSE: CTLT) will begin the first phase of a planned $100 million expansion at its facility in Anagni, Italy, to add biologics drug substance manufacturing... 
Via Benzinga
Moderna's COVID-19 Vaccine Produced Neutralizing Titers Against All Variants Tested
Moderna Inc (NASDAQ: MRNA) has announced new results from in vitro neutralization studies of sera from individuals vaccinated with its COVID-19 vaccine. The COVID-... 
Via Benzinga
Exposures COVID-19
5 Top ETFs With Exposure To Biogen
For the first time in 18 years, there was a new treatment for Alzheimer’s Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that... 
Via Benzinga
Exposures Product Safety
Catalent, Inc. to Present at the Biopharma CEO Investor Forum
From Catalent, Inc.
Via Business Wire
AstraZeneca Seeks Switching COVID-19 Vaccine Production to Catalent Plant: NYT
AstraZeneca Plc (NASDAQ: AZN) is in talks with the U.S. government to shift production of its COVID-19 vaccine from a troubled Emergent BioSolutions Inc’s (... 
Via Benzinga
Exposures COVID-19
Catalent, Inc. to Present at the Jefferies Healthcare Conference and the William Blair Growth Stock Conference
From Catalent, Inc.
Via Business Wire
Catalent, Inc. to Present at the UBS Global Healthcare Virtual Conference
From Catalent, Inc.
Via Business Wire
Catalent Publishes Second Annual Corporate Responsibility Report Highlighting Achievements in an Extraordinary Year for the Pharmaceutical Industry
From Catalent, Inc.
Via Business Wire
Catalent Announces Chief Financial Officer Succession
From Catalent, Inc.
Via Business Wire
FDA Outlines Plan For Restarting Facility Inspections Halted Due To Pandemic
The FDA has published a roadmap for working through the backlog of facility inspections built up during the pandemic when it postponed all routine inspections in March... 
Via Benzinga
Exposures Product Safety
Catalent, Inc. to Present at the BofA Securities 2021 Health Care Conference
From Catalent, Inc.
Via Business Wire
Catalent Buys Promethera's Cell Therapy Subsidiary To Scale-Up Plasmid DNA Efforts
Catalent Inc (NYSE: CTLT) has been expanding rapidly in next-gen cell therapies, and now it has added another facility in Belgium as part of its plan to... 
Via Benzinga
Catalent Inc (CTLT) Q3 2021 Earnings Call Transcript
CTLT earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Catalent, Inc. Reports Third Quarter Fiscal 2021 Results
From Catalent, Inc.
Via Business Wire
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.